The FDA is set to review seven popular peptides that have gained traction among wellness influencers and are backed by figures such as RFK Jr. This advisory panel meeting has sparked discussions about potential easing of peptide restrictions, with implications for a burgeoning market in telehealth and compounded products. As popularity grows, concerns about safety and the science behind these compounds have also been raised, indicating a possible clash between regulatory staff and proponents of peptides. Companies stand ready to capitalize on any favorable outcomes from the review.